Edmond DE Rothschild Holding S.A. Sells 5,460 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Edmond DE Rothschild Holding S.A. trimmed its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 30.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,673 shares of the company’s stock after selling 5,460 shares during the quarter. Edmond DE Rothschild Holding S.A.’s holdings in Teva Pharmaceutical Industries were worth $195,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of TEVA. Ameriprise Financial Inc. grew its stake in Teva Pharmaceutical Industries by 3.9% during the fourth quarter. Ameriprise Financial Inc. now owns 147,649 shares of the company’s stock valued at $3,254,000 after acquiring an additional 5,494 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in shares of Teva Pharmaceutical Industries by 2.3% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 118,394 shares of the company’s stock valued at $2,609,000 after purchasing an additional 2,644 shares during the last quarter. First Manhattan CO. LLC. grew its position in shares of Teva Pharmaceutical Industries by 200.9% during the fourth quarter. First Manhattan CO. LLC. now owns 61,675 shares of the company’s stock valued at $1,359,000 after purchasing an additional 41,175 shares in the last quarter. Ethic Inc. increased its holdings in shares of Teva Pharmaceutical Industries by 45.4% in the fourth quarter. Ethic Inc. now owns 55,323 shares of the company’s stock worth $1,219,000 after purchasing an additional 17,267 shares during the last quarter. Finally, Focus Partners Wealth lifted its position in shares of Teva Pharmaceutical Industries by 8.7% in the fourth quarter. Focus Partners Wealth now owns 38,335 shares of the company’s stock worth $845,000 after buying an additional 3,071 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and raised their price target for the company from $21.00 to $23.00 in a report on Monday, May 12th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. The Goldman Sachs Group began coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, June 6th. They set a “buy” rating and a $24.00 price objective for the company. Truist Financial initiated coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They issued a “buy” rating and a $25.00 target price on the stock. Finally, UBS Group lowered their price target on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a “buy” rating for the company in a report on Thursday, June 26th. Two research analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $24.71.

Teva Pharmaceutical Industries Price Performance

TEVA opened at $18.94 on Friday. The business has a fifty day moving average of $17.04 and a 200 day moving average of $16.40. The stock has a market cap of $21.72 billion, a P/E ratio of -118.35, a PEG ratio of 1.12 and a beta of 0.72. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. The business had revenue of $4.18 billion for the quarter, compared to analyst estimates of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The business’s revenue was up .3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.61 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. As a group, sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Insider Transactions at Teva Pharmaceutical Industries

In other news, insider Placid Jover sold 6,053 shares of the firm’s stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $91,763.48. Following the transaction, the insider directly owned 6,774 shares of the company’s stock, valued at approximately $102,693.84. This trade represents a 47.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Eric A. Hughes sold 52,742 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $799,568.72. The disclosure for this sale can be found here. 0.49% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.